18 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 10 Phase 1, 8 Phase 2, 5 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
| Phase 2 | 8 | Completed 8 |
| Phase 3 | 5 | Completed 3, Not yet recruiting 1, Terminated 1 |
| Phase 4 | 2 | Completed 2 |
Follow Influenza Immunization: new trials by email Literature Review of Influenza Immunization trials Research Report on Influenza Immunization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older IIV-HD (standalone), NVXC19 (EU licensed, standalone), IIV-HD + NVXC19 combination - Immunization, Healthy Volunteers | Phase 3 | Not yet recruiting | Sanofi | 6000 | 2026-11-09 | 2026-10-22 |
| Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe Efluelda® Pre-filled syringe - Influenza Immunization, Healthy Volunteers | Recruiting | Sanofi | 670 | 2026-09-17 | 2026-10-20 | |
| Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older Pandemic flu H5 mRNA vaccine, Placebo - Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 276 | 2024-12-09 | 2026-04-23 |
| Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1) - COVID-19 Immunization, Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi | 980 | 2024-11-19 | 2026-05-05 |
| Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1) - COVID-19 Immunization, Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi | 980 | 2024-11-18 | 2026-05-05 |
| A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire Trivalent Recombinant Influenza Vaccine - Influenza Immunization, Health Volunteers | Completed | Sanofi | 1007 | 2024-11-18 | 2026-04-07 | |
| Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants Influenza Immunization | Completed | Sanofi Pasteur, a Sanofi Company | 5000 | 2024-10-22 | 2026-03-05 | |
| A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429 - Influenza Immunization, Healthy Volunteers | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 908 | 2024-04-01 | 2026-08-04 |
| Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above H3 mRNA / LNP Vaccine, Quadrivalent recombinant influenza Vaccine (RIV4) - Influenza Immunization | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 159 | 2023-04-12 | 2025-09-12 |
| Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine - Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 682 | 2022-12-12 | 2025-03-19 |
| Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD - Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 682 | 2022-11-28 | 2025-03-18 |
| Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years Recombinant influenza vaccine (RIV4), Quadrivalent influenza vaccine (IIV4) - Influenza Immunization | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 366 | 2022-11-10 | 2025-09-09 |
| Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age. Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH - Influenza Immunization | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1308 | 2022-10-27 | 2025-09-09 |
| Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine - Influenza Immunization | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 560 | 2022-10-03 | 2025-01-24 |
| Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine - Influenza Immunization, Healthy Volunteers | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 233 | 2022-06-09 | 2025-09-15 |
| Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older Influenza Hemagglutinin mRNA vaccine, Quadrivalent Recombinant Influenza Vaccine - Influenza, Influenza Immunization | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 388 | 2022-04-11 | 2023-11-07 |
| Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation - Influenza Immunization, Healthy Volunteers | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 90 | 2021-09-08 | 2025-09-12 |
| Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified) - Influenza Immunization, Healthy Volunteers | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 306 | 2021-07-16 | 2025-09-12 |
| Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD), Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD) - Influenza Immunization, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 2100 | 2020-10-21 | 2025-09-23 |
| Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation - Influenza Immunization, Healthy Volunteers | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 90 | 2020-09-16 | 2025-09-12 |
Showing 20 of 21. Sign in to see all of them.
Influenza, Human (21)
Infections (21) · Orthomyxoviridae Infections (21) · RNA Virus Infections (21) · Respiratory Tract Diseases (21) · Respiratory Tract Infections (21) · Virus Diseases (21)
Influenza Vaccines (10) · Vaccines (3) · Vaccines, Combined (2) · 2019-nCoV Vaccine mRNA-1273 (1) · CVnCoV COVID-19 vaccine (1) · Hemagglutinins (1) · Neuraminidase (1) · Saline Solution (1)
Sanofi Pasteur, a Sanofi Company (16) · Sanofi (5)
United States (15) · Puerto Rico (4) · Poland (3) · Australia (2) · Germany (2) · Spain (2) · Belgium (1) · Czechia (1) · France (1) · Honduras (1) · Italy (1) · Japan (1) · Netherlands (1) · South Korea (1) · United Kingdom (1)
2019 (1)